Supplement Figure 1 Volume and cost of three antineoplastic agents from January 2011 to June 2016. (A) volume of brand-name capecitabine and three generic substitutions; (B) volume of brand-name decitabine and five generic substitutions; (C) volume of brand-name imatinib and three generic substitutions; (D) cost of brand-name capecitabine and three generic substitutions; (E) cost of brand-name decitabine and five generic substitutions; (F) cost of brand-name imatinib and three generic substitutions.